Otonomy to Present at the J.P. Morgan Healthcare Conference


SAN DIEGO, Jan. 6, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that David A. Weber, Ph.D., president and chief executive officer, will present at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015 at 3:00 p.m. PT at the Westin St. Francis Hotel in San Francisco. A live audio webcast of the presentation will be available through the Events and Presentations page of the company's corporate website (www.otonomy.com).

About Otonomy

Otonomy is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. Otonomy's proprietary technology provides sustained exposure of drugs to the middle and inner ear following a single intratympanic injection. Otonomy has three product candidates in development. AuriPro™ is an antibiotic that has completed Phase 3 clinical trials in pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery. OTO-104 is a steroid that is in the first of two pivotal clinical studies for the treatment of patients with Ménière's disease. OTO-311 is an NMDA receptor antagonist in development as a treatment for tinnitus. For additional information please visit www.otonomy.com.



            

Coordonnées